Please login to the form below

Not currently logged in
Email:
Password:

SMC

This page shows the latest SMC news and features for those working in and with pharma, biotech and healthcare.

Vertex faces rejection of its CF medicines in Scotland

Vertex faces rejection of its CF medicines in Scotland

The drugs were reviewed through the Patient and Clinician Engagement (PACE) process, which the SMC uses to evaluate end of life medicines and medicines which treat rare conditions. ... According to the SMC, the PACE process allows patient groups and

Latest news

More from news
Approximately 14 fully matching, plus 99 partially matching documents found.

Latest Intelligence

  • The Orkambi row explained The Orkambi row explained

    December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines Consortium (SMC), with interim access possible through the PACS Tier 2 system.

  • The Orkambi blame game The Orkambi blame game

    Leiden also claimed the breakthrough in Scotland came when NICE’s equivalent, the SMC, agreed to ‘flex’ its methodology – something which he and other industry leaders said is vital if NICE

  • Patient involvement in health technology assessment Patient involvement in health technology assessment

    We have developed a Public Involvement Network (PIN) that formalises relationships with each submitting patient group through a registration process to become an SMC Patient Group Partner. ... SMC as a respected partner in developing and shaping all

  • The reality of real-world evidence The reality of real-world evidence

    Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

  • Charting a course for expansion Charting a course for expansion

    The dossiers are going in and the conversations with NICE and the SMC are happening and we're cautiously optimistic.”.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Recent approval for your brand from NICE or SMC? Time to rethink your market access

    Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions. Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment

  • OUTiCO

    Recent approval for your brand from NICE or SMC? Time to rethink your market access.

  • YorkTown

    decision makers associated with pharmaceutical and medical device/diagnostics market access and HEOR; Developing and writing single technology appraisals (STA) (pharmaceutical and medical device) for regulatory institutions (NICE, EMA, SMC and

  • The Holistic Approach to Market Access

    and to provide local prescribing audit data for inclusion into NICE and SMC technical appraisals the gaining of which is a key element in gaining regional prescribing uptake.

  • Hayward Medical Communications

    We had expected the worst with SMC but your contacts, knowledge and experience of the process certainly made the difference for us and the rest as we say is history. ... Needless to say that I would have no problem in recommending you to other companies

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics